Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.

Although the ASCO Plenary session presentation on ALK inhibition with crizotinib was a darling of the entire conference and led to a post I wrote about on the way back from the meeting, there was actually a second presentation on lung cancer in t

One of the key points that has been established in first line treatment of advanced NSCLC is that two drug chemotherapy is superior to one drug chemo. Several trials from a decade ago showed that a two drug "platinum doublet" led to a longer overall survival than either a platinum alone (typically cisplatin at the time that these trials were performed) or another agent, such as paclitaxel alone.